As of Thursday 1 August 2024 Trikafta will be available on the Pharmaceutical Benefits Scheme (PBS) for children aged 2+ with at least one F508del mutation.
This expansion will benefit approximately 290 children, including 100 children gaining access to a modulator for the first time. Thank you to all our community members who are the driving force behind these positive developments.
Read the full communique from CFA’s CEO, Jo Armstrong here.